
Dr Tracy Robson
RCSI
Tracy Robson obtained her
In 2016, she took up
Together with Almac, she led the development of therapeutic peptide derivatives (AD-01 and ALM201) based on FKBPL’s active anti-angiogenic domain. Based on the robust efficacy and excellent safety profile, ALM201, a ‘first-in-class’ FKBPL-based anti-angiogenic therapeutic peptide has completed formulation and toxicology testing and has entered phase I/II cancer clinical trials (EudraCT number: 2014-001175-31).
More recently, ALM201 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in the treatment of ovarian cancer.
IACR 2023 Carer’s Bursary €300
Apply for funding towards additional costs of care while attending conference. Five Bursaries Available.
Registration/ Membership for IACR 2023
Registration for the 59th Annual Conference in the Radisson Blu hotel, Athlone is Now Open.
EACR Membership is Included
The IACR is an affiliated national society and its members benefit from full membership of the EACR.
Biomedical Session Abstracts
Deadline: Midnight, Friday, 20th January 2023
Please note:
- Patrick Johnston Lay submission category is now closed
- Late Breaking Abstracts submitted to the Biomedical Sessions will be considered for Display Poster Presentation.
Social Nursing and Allied Health (SNAH) Abstracts
Deadline: Midnight, Monday, 9th January 2023
SNAH abstract submissions will remain open until Monday 9th January.
Any questions?
Please contact Sinead on: sinead@sineadcassidy.com
Contact Us
Contact Us
Irish Association for Cancer Research
9A Coolkill, Sandyford, Dublin 18
Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations.
Registered Charity Number (RCN): 20030117
Design by patterns.ie
© 2022